Assessing the risks and benefits of treating Helicobacter pylori infection

Hung, Ivan Fan-Ngai; Wong, Benjamin C.Y.

doi:10.1177/1756283x08100279

Cited by 19 publications

(16 citation statements)

References 60 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastric chronic infection due to H. pylori causes many gastrointestinal diseases including peptic ulcers, gastritis, and gastric carcinoma. The prevention of gastric cancer and complications associated with ulcers depends on the successful eradication of H. pylori . In 1997, first‐line treatment was based on a 7‐day triple therapy, using a proton pump inhibitor (PPI) and two of the following antibiotics: clarithromycin, nitro‐imidazole, and amoxicillin .…”

Section: Introductionmentioning

confidence: 99%

Molecular characterization of Helicobacter pylori resistance to rifamycins

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular characterization of Helicobacter pylori resistance to rifamycins

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Although some studies confirmed the inverse associations between these two analyzed phenomena, contradictory results also have been reported. For more details we recommended review papers, such as by Graham et al, 2007;Hung and Wong, 2009;Sharma and Vakil, 2003;Souza and Lima, 2009. Lack of consensus between various studies may be due to many factors, such as difficulties in evaluating the clinical aspects of H. pylori infection or the di erences in the genotype of the infecting strain.…”

Section: Unexpected Consequences Of Helicobacter Pylori Infection/eramentioning

confidence: 99%

The Controversy over Anti-Helicobacter pylori Therapy

Bocian

Jagusztyn-Krynicka²

2012

Pol J Microbiol

View full text Add to dashboard Cite

Helicobacter pylori is a Gram-negative spiral-shaped bacterium, member of epsilon-Proteobacteria specifically colonizing the gastric epithelium of humans. It causes one of the most common infections worldwide, affecting about half of the world's population. However, it should be noted that the prevalence of H. pylori, particularly in the Western world, has significantly decreased coinciding with an increase of some autoimmune and allergic diseases, such as asthma. Various epidemiological studies have also documented a negative association between H. pylori colonization and the presence of GERD (gastroesophageal reflux disease) and risk of esophageal cancer. Additionally, an upward trend of obesity recently observed in inhabitants of developed countries raised a question about the relationship between H. pylori infection and the human body mass index. The first part of this review describes common, recommended anti-H. pylori treatments. The second part, presents the results of recent experiments aimed at evaluating the association between H. pylori infections and gastro-esophageal diseases, the level of stomach hormones, the human body mass index and allergic diseases. Although some studies suggest an inverse association of H. pylori infection with some health problems of the modern world such as asthma, obesity or GERD, H. pylori should be considered as a harmful human pathogen responsible for serious and sometimes lethal diseases. Thus, many scientists advocate the eradication of H. pylori.

show abstract

“…Gastric chronic infection with H. pylori causes many gastrointestinal diseases including peptic ulcers, gastritis, and gastric carcinoma. The prevention of gastric cancer and complications associated with ulcers depends on the successful eradication of H. pylori . In 1997, first‐line treatment was based on a 7‐day triple therapy with a proton‐pump inhibitor (PPI) and two of the following antibiotics: clarithromycin, nitroimidazole, and amoxicillin .…”

Section: Introductionmentioning

confidence: 99%

Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag^®H. pylori + ClariR assay

et al. 2018

View full text Add to dashboard Cite

Background Adapted treatments for Helicobacter pylori infection, guided by determining antimicrobial resistance, are associated with high eradication rates. We evaluated the performance of the Amplidiag® H. pylori + ClariR PCR assay (Amplidiag®) for detecting H. pylori and its clarithromycin resistance from gastric biopsies taken during endoscopy in comparison to culture and our “in‐house” PCR. Materials and Methods A total of 127 gastric biopsies were analyzed (98 adults; 29 children). Culture, PCR Amplidiag®, and in‐house PCR were performed in parallel. The in‐house PCR combined amplification and sequencing of a 267‐bp fragment of the H. pylori 23S rRNA gene. Discrepancies were controlled by amplification of glmM gene. Results For detection of H. pylori, Amplidiag® and the in‐house PCR were concordant in 118 of 127 of cases: 66 negative and 52 positive. Discrepancies were observed in nine cases, all with low bacterial load: Amplidiag® did not detect seven biopsies positive on in‐house PCR but detected two positive biopsies that were negative on in‐house PCR. Among the 19 of 52 (36%) H. pylori cases resistant to clarithromycin, only four biopsies with mixed populations exhibited discordant results between the two PCR methods. The A2142T mutation was not detected by Amplidiag®. With the in‐house PCR and amplified glmM gene as the reference method, the sensitivity and specificity of Amplidiag® was 88.5% (95% confidence interval 83‐94.1) and 100%. Conclusion This study demonstrated the high sensitivity of the PCR‐based Amplidiag® H. pylori test, especially with low H. pylori load, and the probability of its clarithromycin resistance analysis. For clinical use, a well‐designed trial with a large scale of samples may still be needed.

show abstract

Assessing the risks and benefits of treating Helicobacter pylori infection

Cited by 19 publications

References 60 publications

Molecular characterization of Helicobacter pylori resistance to rifamycins

Molecular characterization of Helicobacter pylori resistance to rifamycins

The Controversy over Anti-Helicobacter pylori Therapy

Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag^®H. pylori + ClariR assay

Contact Info

Product

Resources

About

Assessing the risks and benefits of treating Helicobacter pylori infection

Cited by 19 publications

References 60 publications

Molecular characterization of Helicobacter pylori resistance to rifamycins

Molecular characterization of Helicobacter pylori resistance to rifamycins

The Controversy over Anti-Helicobacter pylori Therapy

Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag®H. pylori + ClariR assay

Contact Info

Product

Resources

About

Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag^®H. pylori + ClariR assay